Share Sirolimus (Rapamycin)

Eligibility criteria included being diagnosed with sub-foveal CNV secondary to wet AMD within six months of initial study visit or newly diagnosed patients and a visual acuity of 20/40 to 20/200 in the study eye.  For more information, please contact Celine Delpouys at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Results from a earlier Phase 1 and Phase 2 studies showed that the drug was safe and well-tolerated. The Phase 1 study used three different doses and two different routes of administration (subconjunctival injection and intravitreal injection). Sirolimus administered via subconjunctival injections was as effective, if not more so, than sirolimus administered via intravitreal injection. A subconjunctival injection does not require actually invading the inner eye. Lucentis and Avastin require injections into the eye itself.

There was no evidence of increased intraocular pressure, inflammatory response to treatment, or indication of progression of cataracts.  Patients showed improvements in visual acuity and improvements in retinal thickness.